metformin + biphasic insulin aspart

**Metformin + biphasic insulin aspart** is a fixed combination therapy used in the management of type 2 diabetes mellitus, particularly in patients with inadequate glycemic control on oral agents alone. **Metformin** acts primarily by inhibiting hepatic gluconeogenesis and improving peripheral insulin sensitivity, while **biphasic insulin aspart 30** is a premixed insulin analogue (30% soluble insulin aspart, 70% protaminated insulin aspart) that provides both rapid (prandial) and intermediate (basal) insulin activity. Their combination targets fasting and postprandial glucose, producing improved HbA1c reductions and overall glycemic control, with complementary mechanisms: metformin for insulin sensitivity and hepatic glucose output, insulin aspart for direct glucose uptake and storage. This combination is indicated for type 2 diabetes mellitus, especially in overweight or obese patients or those failing with oral therapy alone[1][2][3].

Other names

BIAsp 30 plus metforminBIAsp30 plus metforminBIAsp-30 plus metformin